𝔖 Bobbio Scriptorium
✦   LIBER   ✦

EZH2, a unique marker of malignancy in effusion cytology

✍ Scribed by Jiang, Huimiao; Gupta, Raavi; Somma, Jonathan

Book ID
120270608
Publisher
John Wiley and Sons
Year
2013
Tongue
English
Weight
523 KB
Volume
42
Category
Article
ISSN
8755-1039

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The use of CDKN2A deletion as a diagnost
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
✍ Illei, Peter B. ;Ladanyi, Marc ;Rusch, Valerie W. ;Zakowski, Maureen F. πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 325 KB

## Background: The distinction between benign reactive mesothelial cells and malignant mesothelial cells in serous effusions is difficult and has an unusually high false negative rate. unfortunately, there are no generally accepted markers to distinguish between benign reactive and malignant mesoth

Reporting risk of malignancy/dysplasia i
Reporting risk of malignancy/dysplasia in cytology
✍ Renshaw, Andrew A. πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 49 KB

C ytology can be used in 2 different ways: as a diagnostic test or as a screening test. As a screening test, a cytologic diagnosis is associated with specific levels of risk for malignancy or dysplasia. There are many different words for communicating this risk. These include the well-known negative